We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting..
The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.
We released GeneReport 1.0